Literature DB >> 8569217

Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.

O Finance1, A Manning, P Chatelain.   

Abstract

We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs. Ischemia was induced by occlusion of the left coronary descending artery (LAD) for 30 min. Premature ventricular complexes (PVCs), ventricular tachycardia (VT), and ventricular fibrillation (VF) were recorded during coronary occlusion. SR 33589 (1.25, 2.50, and 5 mg/kg intravenously, i.v.) markedly reduced the occurrence of ventricular arrhythmias during ischemia. The incidence of VF was reduced from 90% in the control group to 30% (p < 0.05) with 1.25 mg/kg, to 10% (p < 0.001) with 2.50 mg/kg, and to 20% (p < 0.01) with 5 mg/kg. In addition, SR 33589, especially at the two higher doses, caused a sustained reduction in both the incidence of VT and the number of PVCs per minute. In comparison, amiodarone 10 and 20 mg/kg i.v. reduced the incidence of VF (40 and 50%, respectively), but these reductions never reached a level of statistical significance. The incidence of VT and the number of PVCs per minute were also decreased significantly by amiodarone. D,L-sotalol 3 mg/kg i.v. exerted significant anti-arrhythmic activity; the incidence of VF was reduced 20% (p < 0.01), and both the incidence of VT and number of PVC per minute were also reduced. In contrast, lignocaine given as a 2-mg/kg bolus followed by an infusion at 70 micrograms/kg/min had no antiarrhythmic or antifibrillatory activity in this preparation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8569217     DOI: 10.1097/00005344-199510000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Effect of dronedarone on Na+, Ca2+ and HCN channels.

Authors:  Roman Bogdan; Heinz Goegelein; Hartmut Ruetten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-29       Impact factor: 3.000

2.  Dronedarone.

Authors:  Richard L Page; Bashar Hamad; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

3.  Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone.

Authors:  A Varró; J Takács; M Németh; O Hála; L Virág; N Iost; B Baláti; M Agoston; A Vereckei; G Pastor; M Delbruyère; P Gautier; D Nisato; J G Papp
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 4.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 5.  Dronedarone.

Authors:  Sheridan M Hoy; Susan J Keam
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

6.  Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation.

Authors:  Renee M Sullivan; Brian Olshansky
Journal:  Core Evid       Date:  2010-10-21

7.  Reduction of myocardial infarct size by dronedarone in pigs--a pleiotropic action?

Authors:  Andreas Skyschally; Gerd Heusch
Journal:  Cardiovasc Drugs Ther       Date:  2011-06       Impact factor: 3.727

8.  Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.

Authors:  Gerald V Naccarelli; Deborah L Wolbrette; Vadim Levin; Soraya Samii; Javier E Banchs; Erica Penny-Peterson; Mario D Gonzalez
Journal:  Clin Med Insights Cardiol       Date:  2011-10-06

9.  Dronedarone for recurrent ventricular tachycardia: a real alternative?

Authors:  Victor Exposito; Felipe Rodriguez-Entem; Susana Gonzalez-Enriquez; Juan Jose Olalla
Journal:  Indian Pacing Electrophysiol J       Date:  2012-04-30

Review 10.  Dronedarone for atrial fibrillation: a new therapeutic agent.

Authors:  Pawan D Patel; Rohit Bhuriya; Dipal D Patel; Bhaskar L Arora; Param P Singh; Rohit R Arora
Journal:  Vasc Health Risk Manag       Date:  2009-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.